Format

Send to

Choose Destination
Semin Cutan Med Surg. 2018 Sep;37(3):158-162. doi: 10.12788/j.sder.2018.047.

IL-23 inhibitors for moderate-to-severe psoriasis.

Author information

1
Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
2
Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. kegordon@mcw.edu.

Abstract

Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit. At this time, 2 inhibitors of IL-23 p19 have been approved by the United States Food and Drug Administration, guselkumab and tildrakizumab. Two other agents, risankizumab and mirikizumab, have completed phase 3 and phase 2 of development, respectively. Pivotal trials in the development of these agents and clinical use of the approved agents are discussed. Thus far, this class of medications seems to provide a high level of efficacy, along with infrequent dosing and very favorable safety results.

PMID:
30215632
DOI:
10.12788/j.sder.2018.047

Supplemental Content

Full text links

Icon for Frontline Medical Communications Inc
Loading ...
Support Center